NAD+

NAD+ is a central red‑ox coenzyme that people use as an adjunct to raise daily energy and stamina, support disease‑related goals, and pursue longevity or anti‑aging benefits. Community users typically take 50 mg per day (range 1–50 mg) on a daily schedule, whereas clinicians often prescribe 100–200 mg daily subcutaneously. The primary limitation is a thin off‑label evidence base, with most exploratory claims lacking published results, and the most frequently reported side effect is altered sleep or vivid dreams; injection‑site irritation and occasional flushing are reported less often.

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsno dataAnecdotalEfficacyAnecdotalSideEffectsPrice1.51.73.62.35.0

Measured on 5 of 6 axes

Research Evidence

Evidence shape

Human evidence for NAD+ is limited — pilot studies, withdrawn trials, or completed trials without posted results. Off-label / exploratory data exists for 1 additional indication (Cognitive function in aging).

Depthhow much
1 registered trial
1 recruiting / active
Breadthhow many areas
2 indications mapped
1 thin / exploratory · 1 animal-only · 1 single-trial long-tail
Qualityhow rigorous
No completed trials
Breadth and depth19 rows captured
Human
direct clinical signal
1
Animal
translational support
8
In vitro
mechanistic support
10
HighMediumLow

Anecdotal efficacy

NAD+ side effects

Clinical research side effects

Clinical safety table not projected yet.

Anecdotal side effects

Price

Full buying guide →
1
BOC Peptide
--
5000 mg×10
$72.00
$0.01/mg
2
Nurev Peptides
--
1000 mg
$13.99
$0.01/mg
3
Peptigen
GB
1000 mg
$18.50
$0.02/mg
4
Peptigen
GB
1000 mg
$24.83
$0.027/mg
5
Vantixbio
US
1000 mg
$34.00
$0.03/mg
6
Bulk Peptide Supply
unknown
10000 mg×10
$350.00
$0.04/mg

price offers can be sorted by column

1-6 of 342

NAD+ dosing & protocol

How NAD+ is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols
Typical dose
—
0
50 mg
100 mg
150 mg
200 mg
no dose captured for this tier yet
Frequency
not specified
Route
intranasal

No reliably captured dose is reported for the research trials tier; the route noted is intranasal, with frequency and cycling not specified.

Clinician practice
Doctor & published-protocol guidance
Typical dose
200 mg100 mg – 200 mg
typical
0
50 mg
100 mg
150 mg
200 mg
distribution of 3 reported doses · darker = more
Frequency
daily
Route
subQ

Clinician practice runs 100–200 mg subcutaneously daily, with 200 mg as the typical target dose.

Anecdotal
Community-reported real-world use · n = 27
Typical dose
50 mg1 mg – 50 mg
typical
0
50 mg
100 mg
150 mg
200 mg
distribution of 32 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
mixed
Route
subQ

Typical dosing is 50 mg (range 1–50 mg) subcutaneously; among users who gave a schedule, daily and weekly dosing were each reported by 5 respondents, 3×/week by 4, and 2×/week by 1, while 12 did not specify a frequency.

27 sources

Related peptides

SS-31MOTS-cHumaninGlutathioneSLU-PP-332